Kelli D. Barnes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kelli D. Barnes has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Alice N. Hemenway
Clinical Associate Professor/Clinical Pharmacist, Department of Pharmacy Practice, University of Illinois Chicago Retzky College of Pharmacy, Rockford, IL
1 shared publication Amy M. Lehman
The Ohio State University Center for Biostatistics Columbus Ohio
1 shared publication- Anthony W. Olson
Department of Investigational Medicine, Department of Pharmacy, Center for Pharmacy Innovation and Outcomes , Geisinger College of Health Sciences, Danville, PA 17822
1 shared publication - Candis M. Morello
San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, La Jolla, CA 92093, USA
1 shared publication - Candy Tsourounis
Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco , San Francisco, CA 94143
1 shared publication - Cory P. Coffey
The Ohio State University College of Pharmacy, Department of Internal Medicine, Division of General Internal Medicine
1 shared publication
Latest Publications
- Open Access
- 7 August 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (9)
Building on the 2025 National Academies Pharmacy Workshop: health systems financially supported pharmacist roles
Pharmacist services demonstrate a positive impact on healthcare delivery, patient outcomes, and cost of care. Translating this evidence into sustainable funding models demands significant change in healthcare policy and payment that accounts for institutional constraints, payment structures, and scalability requirements. Meanwhile, the gap grows between the positive impact of pharmacist services and reimbursement limited to narrowly defined services or drug product costs. Lack of federally designated provider status and payer-imposed cost containment strategies threaten the financial sustainability of pharmacist services. Future solutions include innovative value-based payment with quality-driven reimbursement, comprehensive medication and care management, and shared financial savings linked to outcomes. Priority funding areas using a shared-savings model include acute and chronic care service lines that cater to high-acuity patients who require high-cost medications and experience frequent care transitions. This model is based on reductions in medication costs, adverse drug-related outcomes, length of stay, and readmissions. A call to action is proposed, focused on policy changes in provider status, adequate payer reimbursement, improving current fee-for-service models and shifting payment models to value-based payment, and removing misaligned financial strategies.
- 7 August 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (9)
Open AccessBuilding on the 2025 National Academies Pharmacy Workshop: health systems financially supported pharmacist roles
Pharmacist services demonstrate a positive impact on healthcare delivery, patient outcomes, and cost of care. Translating this evidence into sustainable funding models demands significant change in healthcare policy and payment that accounts for institutional constraints, payment structures, and scalability requirements. Meanwhile, the gap grows between the positive impact of pharmacist services and reimbursement limited to narrowly defined services or drug product costs. Lack of federally designated provider status and payer-imposed cost containment strategies threaten the financial sustainability of pharmacist services. Future solutions include innovative value-based payment with quality-driven reimbursement, comprehensive medication and care management, and shared financial savings linked to outcomes. Priority funding areas using a shared-savings model include acute and chronic care service lines that cater to high-acuity patients who require high-cost medications and experience frequent care transitions. This model is based on reductions in medication costs, adverse drug-related outcomes, length of stay, and readmissions. A call to action is proposed, focused on policy changes in provider status, adequate payer reimbursement, improving current fee-for-service models and shifting payment models to value-based payment, and removing misaligned financial strategies.
- Open Access
- 1 November 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- p. 102971
Implementation modifications and outcomes of a pharmacist-led primary care remote hypertension service
- 1 November 2025
- Published by Elsevier in Journal of the American Pharmacists Association
- p. 102971
Open AccessImplementation modifications and outcomes of a pharmacist-led primary care remote hypertension service
- 25 October 2014
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 34 (12) , 1330-1335
Pharmacist‐Driven Renal Medication Dosing Intervention in a Primary Care Patient‐Centered Medical Home
Purpose: The purposes of this population management intervention were to identify patients with stage 3, 4, or 5 chronic kidney disease (CKD) and to improve care in a patient‐centered medical home (PCMH). Objectives of the intervention were to (i) increase the identification of CKD, (ii) increase the use of aspirin and angiotensin‐converting enzyme inhibitors (ACE‐Is) or angiotensin II receptor blockers (ARBs) in patients with CKD, and (iii) ensure that all medications prescribed to patients with CKD were dosed appropriately based on renal function.Setting: This intervention was completed at a National Committee for Quality Assurance tier 3 PCMH associated with a major, academic health system.Patients: A list of 328 patients with an estimated glomerular filtration rate of < 60 mL/min per 1.73 m2 was generated using the electronic medical record; 146 patients underwent the intervention.Measurements and Observations: A pharmacist review of the electronic medical record was completed to confirm stage 3, 4, or 5 CKD based on estimated glomerular filtration rate, to ensure that ACE‐Is/ARBs and aspirin were prescribed, and to ensure that all medications were dosed appropriately based on renal dosing adjustment recommendations. Recommendations were made to improve medication use and safety in patients with CKD. Before intervention, 73% of patients were prescribed an ACE‐I/ARB and 72% of patients were prescribed aspirin. After the intervention, use of these medications increased to 77% and 82% of patients, respectively. Pharmacist recommendations to adjust medication dosing based on Cockcroft‐Gault calculated creatinine clearance were made for 138 medications (0.95 medication per patient); 90 (65.2%) recommendations were accepted by the patients’ physicians.Conclusion: These results demonstrate the impact of a pharmacist‐driven renal medication dosing intervention within a PCMH on medication use and safety for patients with CKD.
- 25 October 2014
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 34 (12) , 1330-1335
Pharmacist‐Driven Renal Medication Dosing Intervention in a Primary Care Patient‐Centered Medical Home
Purpose: The purposes of this population management intervention were to identify patients with stage 3, 4, or 5 chronic kidney disease (CKD) and to improve care in a patient‐centered medical home (PCMH). Objectives of the intervention were to (i) increase the identification of CKD, (ii) increase the use of aspirin and angiotensin‐converting enzyme inhibitors (ACE‐Is) or angiotensin II receptor blockers (ARBs) in patients with CKD, and (iii) ensure that all medications prescribed to patients with CKD were dosed appropriately based on renal function.Setting: This intervention was completed at a National Committee for Quality Assurance tier 3 PCMH associated with a major, academic health system.Patients: A list of 328 patients with an estimated glomerular filtration rate of < 60 mL/min per 1.73 m2 was generated using the electronic medical record; 146 patients underwent the intervention.Measurements and Observations: A pharmacist review of the electronic medical record was completed to confirm stage 3, 4, or 5 CKD based on estimated glomerular filtration rate, to ensure that ACE‐Is/ARBs and aspirin were prescribed, and to ensure that all medications were dosed appropriately based on renal dosing adjustment recommendations. Recommendations were made to improve medication use and safety in patients with CKD. Before intervention, 73% of patients were prescribed an ACE‐I/ARB and 72% of patients were prescribed aspirin. After the intervention, use of these medications increased to 77% and 82% of patients, respectively. Pharmacist recommendations to adjust medication dosing based on Cockcroft‐Gault calculated creatinine clearance were made for 138 medications (0.95 medication per patient); 90 (65.2%) recommendations were accepted by the patients’ physicians.Conclusion: These results demonstrate the impact of a pharmacist‐driven renal medication dosing intervention within a PCMH on medication use and safety for patients with CKD.